誉衡药业
(002437)
| 流通市值：44.03亿 | | | 总市值：45.64亿 |
| 流通股本：21.91亿 | | | 总股本：22.71亿 |
| 报告期 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,626,039,306.71 | 2,052,008,504.7 | 1,432,663,200.48 | 681,168,970.96 |
| 营业收入 | 2,626,039,306.71 | 2,052,008,504.7 | 1,432,663,200.48 | 681,168,970.96 |
| 二、营业总成本 | 2,489,293,946.97 | 1,937,036,701.96 | 1,339,988,733 | 636,373,987.48 |
| 营业成本 | 1,092,711,083.38 | 438,699,399.49 | 300,679,982.44 | 146,844,037.63 |
| 税金及附加 | 36,118,668.2 | 28,259,443.13 | 19,826,651.65 | 8,694,980.63 |
| 销售费用 | 1,068,518,701.16 | 1,267,346,151.38 | 882,434,479.8 | 417,332,820.78 |
| 管理费用 | 175,194,905.35 | 115,732,101.81 | 77,866,810.49 | 34,024,266.91 |
| 研发费用 | 85,438,221.66 | 60,334,367.38 | 36,791,497.05 | 13,997,253.96 |
| 财务费用 | 31,312,367.22 | 26,665,238.77 | 22,389,311.57 | 15,480,627.57 |
| 其中:利息费用 | 42,654,181.13 | 34,550,490.05 | 25,879,887.95 | 14,750,986.78 |
| 其中:利息收入 | 18,473,913.07 | 13,926,761.19 | 9,021,475.97 | 4,715,001.25 |
| 加:公允价值变动收益 | -17,934,320.91 | -16,586,728.02 | -13,670,529.08 | -1,825,394.77 |
| 加:投资收益 | -23,438,023.69 | 93,187,121.23 | -44,192,903.96 | -20,774,804.75 |
| 资产处置收益 | 2,839,189.27 | 493,126.58 | 528,803.69 | 164,832.36 |
| 资产减值损失(新) | -3,303,703.22 | -490,192.17 | -122,959.21 | 72,284.69 |
| 信用减值损失(新) | 2,061,254.22 | 1,582,853.27 | 2,686,230 | 1,243,371.06 |
| 其他收益 | 78,076,856.55 | 67,251,711.04 | 13,468,272.24 | 8,540,930.78 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 175,046,611.96 | 260,409,694.67 | 51,371,381.16 | 32,216,202.85 |
| 加:营业外收入 | 2,660,841.44 | 602,985.33 | 377,514.17 | 34,841.25 |
| 减:营业外支出 | 929,304.48 | 814,827.17 | 368,075.5 | 237,579.17 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 176,778,148.92 | 260,197,852.83 | 51,380,819.83 | 32,013,464.93 |
| 减:所得税费用 | 48,077,508.19 | 29,136,775.51 | 19,097,771.51 | 10,143,020.23 |
| 六、净利润 | 128,700,640.73 | 231,061,077.32 | 32,283,048.32 | 21,870,444.7 |
| 持续经营净利润 | 128,700,640.73 | 231,061,077.32 | 32,283,048.32 | 21,870,444.7 |
| 归属于母公司股东的净利润 | 120,334,186.37 | 223,623,549.85 | 28,249,027.25 | 20,058,598.74 |
| 少数股东损益 | 8,366,454.36 | 7,437,527.47 | 4,034,021.07 | 1,811,845.96 |
| (一)基本每股收益 | 0.05 | 0.1 | 0.01 | 0.01 |
| (二)稀释每股收益 | 0.05 | 0.1 | 0.01 | 0.01 |
| 八、其他综合收益 | 855,100.9 | 1,361,428.99 | 1,640,231.73 | -714,035.49 |
| 归属于母公司股东的其他综合收益 | 855,100.9 | 1,361,428.99 | 1,640,231.73 | -714,035.49 |
| 九、综合收益总额 | 129,555,741.63 | 232,422,506.31 | 33,923,280.05 | 21,156,409.21 |
| 归属于母公司股东的综合收益总额 | 121,189,287.27 | 224,984,978.84 | 29,889,258.98 | 19,344,563.25 |
| 归属于少数股东的综合收益总额 | 8,366,454.36 | 7,437,527.47 | 4,034,021.07 | 1,811,845.96 |
| 公告日期 | 2024-04-20 | 2023-10-27 | 2023-07-29 | 2023-04-24 |
| 审计意见(境内) | 标准无保留意见 | | | |